An allogeneic whole cell vaccine for the treatment of non-small-cell lung cancer (NSCLC) developed by Pique Therapeutics Inc. helped people with late-stage, second-line disease achieve a median overall survival (OS) of 12.5 months during a phase II trial, an improvement of 4.1 months over the median OS of patients who received placebo. For the 71 nonsquamous patients enrolled in the study, median OS extended to 15.5 months, besting median OS in the placebo arm by nearly 10 months.